09:46 AM EST - Spectral Medical Inc. : Provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock. The company initiated 2024 with robust site activity to start the new year; Enrolled patient 82 during the first week of January; Post-holiday break, strong screening activity resumed with more than 100 patients screened per week. Spectral Medical Inc.
shares T.EDT are trading unchanged at $0.49.
